摘要
目的探讨表皮生长因子受体(EGFR)基因突变与非小细胞肺癌患者靶向治疗临床疗效的关系。方法选取81例接受吉非替尼口服治疗的非小细胞肺癌患者,对其EGFR基因中21号和19号外显子的突变情况进行测序,根据测序结果将患者分为EGFR突变型组和EGFR野生型组。比较两组患者的临床疗效、基本临床特征、不良反应发生情况和1年无进展生存情况。结果 EGFR基因测序结果显示,EGFR突变型组患者35例,EGFR野生型组患者46例。EGFR突变型组患者的总有效率和疾病控制率均高于EGFR野生型组患者(P﹤0.05)。两组患者的年龄、TNM分期比较,差异均无统计学意义(P﹥0.05);两组患者的性别、病理类型、吸烟史比较,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。EGFR突变型组患者的1年无进展生存率高于EGFR野生型组患者(P﹤0.05)。结论 EGFR基因突变型非小细胞肺癌患者对于靶向药物治疗更敏感,治疗效果更佳,且不良反应与EGFR野生型非小细胞肺癌患者无明显差异,患者的1年无进展生存率相对较高。
Objective To investigate the relationship between epidermal growth factor receptor(EGFR) gene mutation and the clinical efficacy of targeted therapy in patients with non-small cell lung cancer(NSCLC). Method 81 patients with NSCLC who received Gefitinib were selected and divided into EGFR mutation group and EGFR wild type group according to the results of gene sequencingon exon 19 and 21 mutations in EGFR gene. The clinical efficacy, clinical characteristics, adverse events, 1-year progression-free survival were compared between the two groups. Result There were 35 patients in EGFR mutation group and 46 patients in EGFR wild type group according to the results of sequencing. The total efficacy rate and disease control rate of EGFR mutation group were higher than those of EGFR wild type group(P<0.05). The age, TNM stage showed no significant difference between the two groups(P>0.05). There were significant differences in gender, pathological type and smoking history between the two groups(P<0.05). The total occurrence rate of adverse events between the two groups showed no significant difference(P>0.05). The 1-year progressionfree survival rate was higher in the EGFR mutation group than in the EGFR wild type group(P<0.05). Conclusion Patients with EGFR gene mutant in NSCLC are more sensitive to targeted therapy and have better therapeutic effect and higher 1-year progression-free survival rate than those with wild type in EGFR gene, together with similar occurrence rate of adverse events.
作者
张品
沈成
王秀丽
唐大川
许新东
ZHANG Pin;SHEN Cheng;WANG Xiuli;TANG Dachuan;XU Xindong(Department of Respiratory Medicine,Xinyi People’s Hospital,Xinyi 221400,Jiangsu,China)
出处
《癌症进展》
2019年第22期2670-2672,2705,共4页
Oncology Progress
关键词
非小细胞肺癌
表皮生长因子受体
基因突变
靶向治疗
临床疗效
non-small cell lung cancer
epidemal growth factor receptor
gene mutation
targeted therapy
clinical efficacy
